SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use.
Regulatory
COVID Contrarian Tracy Beth Høeg Named as FDA’s Acting CDER Chief
Høeg is the fifth person to lead the Center for Drug Evaluation and Research this year.
December 4, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA
New Approach Methodologies: Redefining Animal Testing Alternatives
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Stacey Adam, PhD, Vice President of Science Partnerships at the Foundation for the National Institutes of Health and Patrick Smith, Senior Vice President, Translational Science at Certara, to discuss the latest regulatory news and the future for new approach methologies (NAMs) development.
December 4, 2025
 · 
1 min read
 · 
BioSpace Insights
crowd and leader
Job Trends
Job Postings in November Tick Up–But So Do Applications
For the second month in a row, job postings on BioSpace increased in key biopharma disciplines. However, application rates also increased.
December 4, 2025
 · 
1 min read
 · 
Chantal Dresner
Aerial view of South San Francisco, California/iSt
Job Trends
7 Companies Hiring in South San Francisco
Job listings in the area have ticked up in the last month. These seven companies are hiring in South San Francisco right now, including scientist and clinical roles.
December 4, 2025
 · 
1 min read
 · 
Chantal Dresner
Burning bird phoenix digital painting.
Duchenne muscular dystrophy
Capricor Heads Back to FDA With Pivotal Results for DMD Cardiomyopathy Therapy
Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” Capricor’s cell therapy deramiocel showed significant benefits in upper-limb function and slowed decline in cardiac function in a Phase III trial.
December 3, 2025
 · 
3 min read
 · 
Heather McKenzie
surreal book concept pages flying out of book
Editorial
Pazdur’s Sudden Exit Leaves Just Three Veterans in FDA’s Senior Ranks
Nearly 90% of senior leaders who were at the FDA a year ago are no longer with the agency, a BioSpace analysis shows. None remain from the Office of the Commissioner.
December 3, 2025
 · 
4 min read
 · 
Jef Akst
Pictured: Bristol Myers Squibb office in California
Alzheimer’s disease
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study
Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a “significant development.”
December 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neuroscience
Harmony’s Dravet Drug Halves Monthly Seizures in Late-Stage Study
The Phase III, open-label extension study suggests EPX-100 has a “positive” risk/benefit profile for the treatment of Dravet syndrome, analysts at H.C. Wainwright & Co. said Tuesday.
December 3, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Regulatory
FDA Moves to Cut Back on Testing Antibodies on Primates
For certain monospecific antibodies, three-month toxicology studies plus other supportive evidence will suffice, eliminating the need for six-month testing.
December 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS